PolyPid logo

PolyPidNASDAQ: PYPD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

26 June 2020

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$15.83 M
-89%vs. 3y high
22%vs. sector
-vs. 3y high
-vs. sector
-26%vs. 3y high
92%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Fri, 01 Nov 2024 13:30:00 GMT
$3.30+$0.10(+3.12%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

PYPD Latest News

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
globenewswire.com30 October 2024 Sentiment: POSITIVE

PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 13, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
globenewswire.com21 October 2024 Sentiment: POSITIVE

SHIELD I Study is One of the Largest Phase 3 Trials in the Prevention of SSIs in Colorectal Resection Conducted in Over a Decade

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
globenewswire.com01 October 2024 Sentiment: POSITIVE

Unblinded Interim Analysis to be Conducted During the Current Quarter Top-line Results Anticipated in First Quarter of 2025 PETACH TIKVA, Israel, Oct. 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the last patient required in order to conduct the planned unblinded interim analysis in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
globenewswire.com01 August 2024 Sentiment: POSITIVE

Funding Extends Company's Cash Runway into Second Quarter 2025, which is beyond the Anticipated Timing for SHIELD II Top-line Results if Warrants are Fully Exercised

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial
globenewswire.com10 June 2024 Sentiment: POSITIVE

PETACH TIKVA, Israel, June 10, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a virtual Key Opinion Leader (KOL) event on Monday, June 17, 2024, at 10:00 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company's ongoing D-PLEX100 Phase 3 trial. To register, click here .

PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research19 February 2024 Sentiment: POSITIVE

PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript
Seeking Alpha14 February 2024 Sentiment: NEUTRAL

PolyPid Ltd (PYPD) Q4 2023 Earnings Call Transcript

PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript
Seeking Alpha12 November 2023 Sentiment: NEUTRAL

PolyPid Ltd. (NASDAQ:PYPD ) Q3 2023 Earnings Conference Call November 11, 2023 8:00 AM ET Company Participants Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer Conference Call Participants Roy Buchanan - JMP Raghuram Selvaraju - H.C.

PolyPid Ltd (PYPD) Q2 2023 Earnings Call Transcript
Seeking Alpha09 August 2023 Sentiment: POSITIVE

PolyPid Ltd (NASDAQ:PYPD ) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET Company Participants Brian Ritchie - LifeSci Advisors Dikla Akselbrad - CEO & Director Jonny Missulawin - CFO Ori Warshavsky - COO Conference Call Participants Douglas Buchanan - JMP Securities Operator Greetings, and welcome to the PolyPid Second Quarter 2023 Conference Call. [Operator Instructions].

What type of business is PolyPid?

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

What sector is PolyPid in?

PolyPid is in the Healthcare sector

What industry is PolyPid in?

PolyPid is in the Biotechnology industry

What country is PolyPid from?

PolyPid is headquartered in Israel

When did PolyPid go public?

PolyPid initial public offering (IPO) was on 26 June 2020

What is PolyPid website?

https://www.polypid.com

Is PolyPid in the S&P 500?

No, PolyPid is not included in the S&P 500 index

Is PolyPid in the NASDAQ 100?

No, PolyPid is not included in the NASDAQ 100 index

Is PolyPid in the Dow Jones?

No, PolyPid is not included in the Dow Jones index

When was PolyPid the previous earnings report?

No data

When does PolyPid earnings report?

The next expected earnings date for PolyPid is 13 November 2024